… Gefitinib, an inhibitor of epidermal growth factor receptor tyrosine kinase (EGFR-TK), potently
suppresses the growth of … We therefore studied the antineoplastic potency of gefitinib in …

… cisplatin/vinorelbine alone in the first-line treatment of patients (pts) with epidermal growth
factor receptor (EGFR) positive advanced non-small-cell lung cancer (NSCLC). Proc Am Soc …

… Gefitinib is a small molecule tyrosine kinase inhibitor of epidermal growth factor receptor (…
) obtaining objective response when treated with gefitinib harbour activating mutations in the …

… Mutations of epidermal growth factor receptor in the current study. Numbers in parentheses
indicate the number of patients with the mutation. Exons 18, 19, 21, and 23 were analyzed in …

… Progression-free survival was calculated from the date of initiation of gefitinib to … of gefitinib
treatment to the date of death. Statistical analyses of clinical data and epidermal growth factor …

… who are candidates for surgical treatment in Japan. In our … family, including the epidermal
growth factor receptor (EGFR… including epidermal growth factor and transforming growth factor …

… of first-line epidermal growth factor receptor (EGFR) tyrosine … % of patients in the gefitinib
group did not receive subsequent … The median duration of gefitinib treatment was longer in the …

… Effect of epidermal growth factor receptor tyrosine kinase domain mutations on the outcome
of patients with non-small cell lung cancer treated with epidermal growth factor receptor …

… These findings support the use of gefitinib for the treatment of patients with NSCLC who …
with the safety of gefitinib, justifies its use in patients previously treated with chemotherapy. …

… This subset of patients is representative of the total patient population treated with gefitinib
in our centre; baseline patient demographics are presented in Table 1. Most patients had …